---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002162"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:45:41.406652+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs

## Summary
- Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.
- Cash $1.2B including Pfizer payment; Q4 net loss $64.7M ($0.95/shr), FY net loss $370.6M ($5.77/shr).
- Planned H2 2022 IND submissions: BEAM-101 (SCD Phase 1/2), BEAM-102 (SCD), BEAM-201 (T-ALL/TLL).
- IND-enabling studies for BEAM-301 (liver-targeted GSDIa) in 2022; second CAR-T candidate nomination due.
- R&D expenses $96.8M Q4 (up from $32.5M), G&A $17.8M Q4 (up from $8.4M) YoY.

## SEC filing metadata
- accession: 0000950170-22-002162
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/0000950170-22-002162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/beam-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002162
- JSON: https://secwatch.observer/filing/0000950170-22-002162.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.